In prespecified analyses, EYLEA reduced central retinal thickness2-4
Mean Change in Central Retinal Thickness, as Measured by OCT,* at 24 Weeks From Baseline2-4,†
The results of these prespecified analyses require cautious interpretation and could represent chance findings, as a multiplicity adjustment has not been applied.
Anatomic measures were not used to influence treatment decisions1
VIBRANT clinical study design: Randomized, multicenter, double-masked, controlled clinical study in which patients with Macular Edema following BRVO (N=181; age range: 42-94 years, with a mean of 65 years) were randomized to receive 1) EYLEA 2 mg administered every 4 weeks or 2) laser photocoagulation administered at baseline and subsequently as needed (control group).
The primary efficacy endpoint was the proportion of patients who gained ≥15 letters in best-corrected visual acuity at week 24 compared to baseline.
COPERNICUS and GALILEO clinical study designs: Randomized, multicenter, double-masked, sham-controlled clinical studies in patients with Macular Edema following CRVO (N=358; age range: 22-89 years, with a mean of 64 years). Patients were assigned in a 3:2 ratio to either 1) EYLEA 2 mg administered every 4 weeks (monthly) for the first 6 months or 2) sham injections (control) administered every 4 weeks (monthly) for a total of 6 injections.
In both studies, the primary efficacy endpoint was the proportion of patients who gained ≥15 letters in best-corrected visual acuity at week 24 compared to baseline.
- Optical coherence tomography.
- Last observation carried forward; full analysis set.